Molecular Profile Detail

Profile Name SMO V321M
Gene Variant Detail

SMO V321M (gain of function - predicted)

Relevant Treatment Approaches GLI1/2 inhibitor SMO Inhibitor

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
SMO V321M Advanced Solid Tumor resistant SMO Inhibitor Vismodegib Preclinical Actionable In a preclinical study, a transformed cell line expressing SMO V321M demonstrated resistance to Erivedge (vismodegib) (PMID: 25759020). 25759020
SMO V321M basal cell carcinoma predicted - resistant SMO Inhibitor Vismodegib Clinical Study Actionable In a clinical case study, a de novo SMO V321M mutation was identified in a recurrent lesion from a basal cell carcinoma patient following an initial twenty week response to Erivedge (vismodegib) (PMID: 25199678). 25199678
SMO V321M Advanced Solid Tumor decreased response SMO Inhibitor Taladegib Preclinical Actionable In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO T241M on the background of PTCH1 and TP53 deletion demonstrated reduced response to LY2940680 induced growth inhibition in cell culture (PMID: 25759019). 25759019
SMO V321M Advanced Solid Tumor sensitive JQ1 Preclinical Actionable In a preclinical study, JQ1 inhibited proliferation of primary cerebellar granule neuron precursor cells over expressing SMO V321M on the background of PTCH1 and TP53 deletion in cell culture (PMID: 25759019). 25759019
SMO V321M Advanced Solid Tumor decreased response SMO Inhibitor Sonidegib Preclinical Actionable In a preclinical study, primary cerebellar granule neuron precursor cells over expressing SMO C469Y on the background of PTCH1 and TP53 deletion demonstrated reduced response to Odomzo (sonidegib) induced growth inhibition in cell culture (PMID: 25759019). 25759019
Clinical Trial Phase Therapies Title Recruitment Status